The Pharmaceutical Industry: Key events and trends shaping its current status and future direction
 
Report

The Pharmaceutical Industry: Key events and trends shaping its current status and future directionMarket StudyThe Pharmaceutical Industry: Key events and trends shaping its current status and future direction is a marketing resource from Datamonitor, a leading provider of online data, analytic and forecasting platforms for key vertical sectors.

From:
$7600
 
Introduction

Despite a tough year in 2005 in terms of the regulatory environment and public opinion, with the withdrawal of Vioxx still at the forefront of peoples' minds, a number of leading pharmas continued to drive impressive growth. Biologicals continued to lead the market in terms of growth with Genentech's cancer focused portfolio driving the fastest growth in 2005 and forecast to do the same in 2006.



Scope


  • Examines the performance of the leading pharma companies in 2005 to reveal the winners and losers by sales growth and share price performance
  • Identifies the products driving market growth and considers the patent expiries that are expected to slow that growth over the coming year
  • Explores the key trends that will shape the pharmaceutical market in 2006 and beyond


  • Highlights

    Genentech was the fastest growing of the top 50 pharma and biotech companies in 2005. The company has been one of the major success stories of the last few years, and backs up that reputation with an impressive 46.4% sales growth rate in 2005, building on sales of $3,749m in 2004. Datamonitor also forecasts it to have the fastest growth in 2006.



    2005 was characterized by a lack of mega-mergers between the industry heavyweights, as the major players questioned the value of such huge-scale deals. Nevertheless, it has remained popular to make small, incremental acquisitions to acquire pipeline products or increase presence in specific therapeutic areas a trend expected to continue



    While there were a number of new product launches in 2005, 2006 looks set to see the launch of products with greater potential. Sanofi-Aventis' Acomplia for the treatment of obesity and smoking cessation and Pfizer's inhalable insulin Exubera both have considerable sales potential



    Reasons to Purchase

  • Benchmark the leading companies in terms of sales and share price performance in 2005
  • Uncover the products driving growth in the pharmaceutical industry as well as the key patent expiries likely to restrict it
  • Assess the key trends that will shape the future pharmaceutical market
Report Details:
Publisher:
Datamonitor
Type:
Market Study - March 2006
Number of pages:
87
First Publication Date:
29/3/2006
 
 
 
Copyright © Chiltern Magazine Services Ltd | Email: admin@cmsinfo.com | Tel: +(1) 508 861 0401